Amnion-derived cells as a reliable resource for next-generation regenerative medicine

Umezawa, Akihiro; Hasegawa, Akihiro; Inoue, Momoko; Tanuma-Takahashi, Akiko; Kajiwara, Kazuhiro; Makino, Hidenari; Chikazawa, Emi; Okamoto, Aikou

doi:10.1016/j.placenta.2019.06.381

Cited by 30 publications

(26 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, the response to these cells was dependent on the timing of administration and the effects were best observed when they were administered at an early stage of injury (142,143). Umezawa et al (156) showed that placental amnion-derived cells can be reprogrammed to induced pluripotent stem cells. These cells maintained normal karyotype and chromosomal stability over a long period of passages.…”

Section: Human Amniotic Epithelial Cells (Haecs)mentioning

confidence: 99%

See 1 more Smart Citation

A Review of Placenta and Umbilical Cord-Derived Stem Cells and the Immunomodulatory Basis of Their Therapeutic Potential in Bronchopulmonary Dysplasia

et al. 2021

View full text Add to dashboard Cite

Bronchopulmonary dysplasia (BPD) is a devastating lung disorder of preterm infants as a result of an aberrant reparative response following exposures to various antenatal and postnatal insults. Despite sophisticated medical treatment in this modern era, the incidence of BPD remains unabated. The current strategies to prevent and treat BPD have met with limited success. The emergence of stem cell therapy may be a potential breakthrough in mitigating this complex chronic lung disorder. Over the last two decades, the human placenta and umbilical cord have gained increasing attention as a highly potential source of stem cells. Placenta-derived stem cells (PDSCs) and umbilical cord-derived stem cells (UCDSCs) display several advantages such as immune tolerance and are generally devoid of ethical constraints, in addition to their stemness qualities. They possess the characteristics of both embryonic and mesenchymal stromal/stem cells. Recently, there are many preclinical studies investigating the use of these cells as therapeutic agents in neonatal disease models for clinical applications. In this review, we describe the preclinical and clinical studies using PDSCs and UCDSCs as treatment in animal models of BPD. The source of these stem cells, routes of administration, and effects on immunomodulation, inflammation and regeneration in the injured lung are also discussed. Lastly, a brief description summarized the completed and ongoing clinical trials using PDSCs and UCDSCs as therapeutic agents in preventing or treating BPD. Due to the complexity of BPD, the development of a safe and efficient therapeutic agent remains a major challenge to both clinicians and researchers.

show abstract

Section: Human Amniotic Epithelial Cells (Haecs)mentioning

confidence: 99%

“…These cells maintained normal karyotype and chromosomal stability over a long period of passages. It can be easily isolated and expanded for industrial production of large quantities (156).…”

Section: Human Amniotic Epithelial Cells (Haecs)mentioning

confidence: 99%

A Review of Placenta and Umbilical Cord-Derived Stem Cells and the Immunomodulatory Basis of Their Therapeutic Potential in Bronchopulmonary Dysplasia

et al. 2021

View full text Add to dashboard Cite

show abstract

“…With the development of research on seed cells, the researchers have found that human amniotic mesenchymal stem cells, placental mesenchymal stem cells, bone marrow mesenchymal stem cells and adipose mesenchymal stem cells have the characteristics of low immunogenicity, which can inhibit the proliferation and function of major immune cell groups, including T cells, and they are also easy to isolate and culture, and have pluripotent differentiation. [18] Therefore, they are not easily recognized by the host immune system and can be applied to allograft or xenograft. Thus, they are potential and valuable seed cells.…”

Section: Seed Cellsmentioning

confidence: 99%

Research Progress on Tissue Engineering of Main Tissues and Organs of Human Body

Jin

2021

E3S Web Conf.

View full text Add to dashboard Cite

The injury and failure diseases of human tissues and organs, such as heart failure and chronic kidney disease, seriously threaten human health and life safety. At present, however, organ transplantation has obvious limitations, and tissue engineering is considered as a potential alternative therapy. Tissue engineering uses the construction of cells, biomaterials and bioreactors to develop three-dimensional artificial tissues and organs for the enhancement, repair and replacement of damaged or diseased tissues and organs, which contributes to the fundamental solutions of diseases of tissues and organs as well as to the improvement of human health. This paper introduces the research progress of tissue engineering technology in the field of living organs from three aspects: seed cells, application of growth factors and biomimetic preparation of functionalized scaffold materials, hoping to provide help and ideas for the research and industrial development of the repair and reconstruction of human organs.

show abstract

“…Maternal and fetal immune cells interact in the decidua, a membrane of maternal origin that plays an important role in feto-maternal tolerance [24]. Cells isolated from different parts of placental tissues, including amnion [25,26], decidua [26,27], and umbilical cord have been studied for their multipotent differentiation capacities [28], but most importantly for their immunomodulatory and anti-inflammatory properties. Intact amniotic membranes from term placentas have been used for almost a century to treat severe burn injuries, and, later, corneal wounds, and are known for their ability for tissue repair without being rejected [29].…”

Section: The Rationale For Human Placentaand Amnion-derived Cell Therapymentioning

confidence: 99%

Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy

Berishvili

Kaiser

Cohen

et al. 2020

Stem Cell Rev and Rep

View full text Add to dashboard Cite

Nearly 500'000 fatalities due to COVID-19 have been reported globally and the death toll is still rising. Most deaths are due to acute respiratory distress syndrome (ARDS), as a result of an excessive immune response and a cytokine storm elicited by severe SARS-CoV-2 lung infection, rather than by a direct cytopathic effect of the virus. In the most severe forms of the disease therapies should aim primarily at dampening the uncontrolled inflammatory/immune response responsible for most fatalities. Pharmacological agents-antiviral and anti-inflammatory molecules-have not been able so far to achieve compelling results for the control of severe COVID-19 pneumonia. Cells derived from the placenta and/or fetal membranes, in particular amniotic epithelial cells (AEC) and decidual stromal cells (DSC), have established, well-characterized, potent anti-inflammatory and immune-modulatory properties that make them attractive candidates for a cell-based therapy of COVID19 pneumonia. Placenta-derived cells are easy to procure from a perennial source and pose minimal ethical issues for their utilization. In view of the existing clinical evidence for the innocuousness and efficiency of systemic administration of DSCs or AECs in similar conditions, we advocate for the initiation of clinical trials using this strategy in the treatment of severe COVID-19 disease.

show abstract

Amnion-derived cells as a reliable resource for next-generation regenerative medicine

Cited by 30 publications

References 51 publications

A Review of Placenta and Umbilical Cord-Derived Stem Cells and the Immunomodulatory Basis of Their Therapeutic Potential in Bronchopulmonary Dysplasia

A Review of Placenta and Umbilical Cord-Derived Stem Cells and the Immunomodulatory Basis of Their Therapeutic Potential in Bronchopulmonary Dysplasia

Research Progress on Tissue Engineering of Main Tissues and Organs of Human Body

Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy

Contact Info

Product

Resources

About